AstraZeneca: Japan approves chronic heart failure drug
(CercleFinance.com) - AstraZeneca said on Monday that the Japanese health authorities have approved a diabetes drug for a specific type of chronic heart failure.
The biopharmaceutical company said that Japan's Ministry of Health, Labor and Welfare has approved the company's Forxiga for people suffering for chronic heart failure with reduced ejection fraction in adult patients with and without type-2 diabetes.
Reduced ejection fraction occurs when the left ventricle muscle is not able to contract sufficiently, and therefore expels less oxygen-rich blood into the body.
Copyright (c) 2020 CercleFinance.com. All rights reserved.